574 related articles for article (PubMed ID: 32193378)
1. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Färkkilä A; Gulhan DC; Casado J; Jacobson CA; Nguyen H; Kochupurakkal B; Maliga Z; Yapp C; Chen YA; Schapiro D; Zhou Y; Graham JR; Dezube BJ; Munster P; Santagata S; Garcia E; Rodig S; Lako A; Chowdhury D; Shapiro GI; Matulonis UA; Park PJ; Hautaniemi S; Sorger PK; Swisher EM; D'Andrea AD; Konstantinopoulos PA
Nat Commun; 2020 Mar; 11(1):1459. PubMed ID: 32193378
[TBL] [Abstract][Full Text] [Related]
2. Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.
Mutch D; Voulgari A; Chen XM; Bradley WH; Oaknin A; Perez Fidalgo JA; Montosa FG; Herraez AC; Holloway RW; Powell MA; Nowicka M; Schaefer G; Merchant M; Yan Y
Cancer; 2024 Jun; 130(11):1940-1951. PubMed ID: 38288862
[TBL] [Abstract][Full Text] [Related]
3. Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer.
Lee EK; Konstantinopoulos PA
Trends Cancer; 2019 Sep; 5(9):524-528. PubMed ID: 31474356
[TBL] [Abstract][Full Text] [Related]
4. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a
Gong J; Wang C; Lee PP; Chu P; Fakih M
J Natl Compr Canc Netw; 2017 Feb; 15(2):142-147. PubMed ID: 28188185
[TBL] [Abstract][Full Text] [Related]
5. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.
Wang Z; Sun K; Xiao Y; Feng B; Mikule K; Ma X; Feng N; Vellano CP; Federico L; Marszalek JR; Mills GB; Hanke J; Ramaswamy S; Wang J
Sci Rep; 2019 Feb; 9(1):1853. PubMed ID: 30755715
[TBL] [Abstract][Full Text] [Related]
6. Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement.
Bellone S; Buza N; Choi J; Zammataro L; Gay L; Elvin J; Rimm DL; Liu Y; Ratner ES; Schwartz PE; Santin AD
Clin Cancer Res; 2018 Jul; 24(14):3282-3291. PubMed ID: 29351920
[No Abstract] [Full Text] [Related]
7. Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model.
Lee EJ; Kim JH; Kim TI; Kim YJ; Pak ME; Jeon CH; Park YJ; Li W; Kim YS; Choi JG; Chung HS
Front Immunol; 2021; 12():737076. PubMed ID: 34659228
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
9. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
[TBL] [Abstract][Full Text] [Related]
10. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
11. Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?
Ledermann JA
Gynecol Oncol; 2019 May; 153(2):213-214. PubMed ID: 31027611
[No Abstract] [Full Text] [Related]
12. Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer.
Meng J; Peng J; Feng J; Maurer J; Li X; Li Y; Yao S; Chu R; Pan X; Li J; Zhang T; Liu L; Zhang Q; Yuan Z; Bu H; Song K; Kong B
J Transl Med; 2021 Oct; 19(1):415. PubMed ID: 34620163
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.
Passiglia F; Bironzo P; Righi L; Listì A; Arizio F; Novello S; Volante M; Scagliotti GV
Clin Lung Cancer; 2021 Jan; 22(1):e63-e66. PubMed ID: 32917522
[TBL] [Abstract][Full Text] [Related]
14. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
15. TOX-expressing terminally exhausted tumor-infiltrating CD8
Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
[TBL] [Abstract][Full Text] [Related]
16. Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.
Liu Y; Zugazagoitia J; Ahmed FS; Henick BS; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
Clin Cancer Res; 2020 Feb; 26(4):970-977. PubMed ID: 31615933
[TBL] [Abstract][Full Text] [Related]
17. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
18. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
Mesnage SJL; Auguste A; Genestie C; Dunant A; Pain E; Drusch F; Gouy S; Morice P; Bentivegna E; Lhomme C; Pautier P; Michels J; Le Formal A; Cheaib B; Adam J; Leary AF
Ann Oncol; 2017 Mar; 28(3):651-657. PubMed ID: 27864219
[TBL] [Abstract][Full Text] [Related]
20. Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor.
Xue C; Xu Y; Ye W; Xie Q; Gao H; Xu B; Zhang D; Jiang J
Gynecol Oncol; 2020 Apr; 157(1):222-233. PubMed ID: 31987601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
